Johimbin

Iz Wikipedije, slobodne enciklopedije
Johimbin
(IUPAC) ime
17α-hidroksi-johimban-16α-
metil estar karboksilne kiseline
Klinički podaci
Robne marke Yocon
Identifikatori
CAS broj 146-48-5
ATC kod G04BE04 QV03AB93
PubChem[1][2] 8969
DrugBank DB01392
ChemSpider[3] 8622
UNII 2Y49VWD90Q YesY
ChEBI CHEBI:10093 YesY
ChEMBL[4] CHEMBL15245 YesY
Hemijski podaci
Formula C21H26N2O3 
Mol. masa 354,44 g/mol (baza)
390,90 g/mol (hidrohlorid)
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status OTC
Način primene Oralno

Johimbin je alkaloid sa stimulantnim i afrodizijskim dejstvom koji se prirodno javlja u biljci Pausinystalia yohimbe. On se takođe prirodno javlja u Rauwolfia serpentina i Alchornea floribunda, zajedno sa nekoliko drugih alkaloida. Johimbin je korišten kao dijetarni suplement u obliku biljnog ekstrakta i kao lek na recepat u čistoj formi za tretman seksualne disfunkcije. Johimbin je izučavan kao lek za tip 2 dijabetes.[5]

Farmakologija[uredi - уреди | uredi izvor]

Johimbin ima visok afinitet za α2-adrenergički receptor, umereni afinitet za α1-adrenergički, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F, 5-HT2B, i D2 receptore, i slab afinitet za 5-HT1E, 5-HT2A, 5-HT5A, 5-HT7, i D3 receptore.[6][7] On deluje kao antagonist na α1-adrenergičkom, α2-adrenergičkom, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, i D2, i kao parcijalni agonist na 5-HT1A.[6][8][9][10]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  5. Rosengren, A. H.; Jokubka, R.; Tojjar, D.; Granhall, C.; Hansson, O.; Li, D.-Q.; Nagaraj, V.; Reinbothe, T. M.; Tuncel, J. (2009). "Overexpression of Alpha2A-Adrenergic Receptors Contributes to Type 2 Diabetes". Science 327 (5962): 217–20. PMID 19965390. doi:10.1126/science.1176827. 
  6. 6,0 6,1 Millan MJ; Newman-Tancredi A; Audinot V et al. (February 2000). "Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states". Synapse 35 (2): 79–95. PMID 10611634. doi:10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X. 
  7. "PDSP Ki Database". http://pdsp.med.unc.edu/pdsp.php#search. 
  8. Arthur JM, Casañas SJ, Raymond JR (June 1993). "Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors". Biochemical Pharmacology 45 (11): 2337–41. PMID 8517875. doi:10.1016/0006-2952(93)90208-E. 
  9. Kaumann AJ (June 1983). "Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology 323 (2): 149–54. PMID 6136920. doi:10.1007/BF00634263. 
  10. Baxter GS, Murphy OE, Blackburn TP (May 1994). "Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle". British Journal of Pharmacology 112 (1): 323–31. PMC 1910288. PMID 8032658. 

Spoljašnje veze[uredi - уреди | uredi izvor]


Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).